ID

32230

Descrição

Lithium Drug-Drug Interaction Study With Lurasidone HCl; ODM derived from: https://clinicaltrials.gov/show/NCT01074073

Link

https://clinicaltrials.gov/show/NCT01074073

Palavras-chave

Versões (1)
  1. 24/10/2018 24/10/2018 -
Titular dos direitos

See clinicaltrials.gov

Transferido a

24 de outubro de 2018

DOI

Para um pedido faça login.

Licença

Creative Commons BY 4.0
Comentários do modelo :

Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.

Voltar para os comentários do modelo
Comentários do grupo de itens para :

Comentários do item para :

Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.

Eligibility Schizophrenia NCT01074073

Inglês

Eligibility Schizophrenia NCT01074073

1 Formulários  
Inclusion Criteria
Descrição

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform.
Descrição

Schizophrenia | Schizoaffective Disorder | Schizophreniform Disorders

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0036341
UMLS CUI [2]
C0036337
UMLS CUI [3]
C0036358
2. females who participate in this study:
Descrição

Gender

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0079399
are unable to have children-or-
Descrição

Infertility

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0021359
are willing to remain abstinent from day -5 until 90 days after discharge;
Descrição

Sexual Abstinence Willing

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0036899
UMLS CUI [1,2]
C0600109
3. males must be willing to remain sexually abstinent or use an effective method of birth control (e.g. condom) from day -5 until 90 days after discharge.
Descrição

Gender Sexual Abstinence Willing | Gender Contraceptive methods | Condoms, Male

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0079399
UMLS CUI [1,2]
C0036899
UMLS CUI [1,3]
C0600109
UMLS CUI [2,1]
C0079399
UMLS CUI [2,2]
C0700589
UMLS CUI [3]
C0009653
4. able and agree to remain off of prior antipsychotic medication for the duration of the study.
Descrição

Antipsychotic Agents Absent

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0040615
UMLS CUI [1,2]
C0332197
Exclusion Criteria
Descrição

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. presence or history (within the last year) of a medical or surgical condition (e.g. gastrointestinal disease) that might interfere with the absorption, metabolism, or excretion of orally administered lurasidone.
Descrição

Medical condition Interferes with Absorption Lurasidone Oral Product | Medical condition Interferes with Metabolism Lurasidone Oral Product | Medical condition Interferes with Excretion Lurasidone Oral Product | Gastrointestinal Diseases | Operative Surgical Procedure Interferes with Absorption Lurasidone Oral Product | Operative Surgical Procedure Interferes with Metabolism Lurasidone Oral Product | Operative Surgical Procedure Interferes with Excretion Lurasidone Oral Product

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C3843040
UMLS CUI [1,2]
C0521102
UMLS CUI [1,3]
C0237442
UMLS CUI [1,4]
C3218141
UMLS CUI [2,1]
C3843040
UMLS CUI [2,2]
C0521102
UMLS CUI [2,3]
C0025519
UMLS CUI [2,4]
C3218141
UMLS CUI [3,1]
C3843040
UMLS CUI [3,2]
C0521102
UMLS CUI [3,3]
C0221102
UMLS CUI [3,4]
C3218141
UMLS CUI [4]
C0017178
UMLS CUI [5,1]
C0543467
UMLS CUI [5,2]
C0521102
UMLS CUI [5,3]
C0237442
UMLS CUI [5,4]
C3218141
UMLS CUI [6,1]
C0543467
UMLS CUI [6,2]
C0521102
UMLS CUI [6,3]
C0025519
UMLS CUI [6,4]
C3218141
UMLS CUI [7,1]
C0543467
UMLS CUI [7,2]
C0521102
UMLS CUI [7,3]
C0221102
UMLS CUI [7,4]
C3218141
2. positive test results within 30 days prior to the start of the study for:
Descrição

Positive Laboratory Test Result

Tipo de dados

boolean

Alias
UMLS CUI [1]
C1335447
3. participated in another clinical trial or receiving an investigational product within 30 days prior to drug administration.
Descrição

Study Subject Participation Status | Investigational New Drugs

Tipo de dados

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0013230
4. use of concomitant medications that prolong the qt/qtc interval within 14 days prior to day - 5 to follow-up
Descrição

Pharmaceutical Preparations Causing Prolonged QT interval | Pharmaceutical Preparations Causing Prolonged QTc interval

Tipo de dados

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0678227
UMLS CUI [1,3]
C0151878
UMLS CUI [2,1]
C0013227
UMLS CUI [2,2]
C0678227
UMLS CUI [2,3]
C1560305
5. use of a monoamine oxidase inhibitor within 21 days prior to day 1 to restabilization.
Descrição

Monoamine Oxidase Inhibitors

Tipo de dados

boolean

Alias
UMLS CUI [1]
C0026457
6. received depot neuroleptics unless the last injection was at least 1 treatment cycle before day -5.
Descrição

Injection of depot antipsychotic agent

Tipo de dados

boolean

Alias
UMLS CUI [1]
C2585377
Voltar ao início da página

Similar models

Eligibility Schizophrenia NCT01074073

1 Formulários
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Item Group
C1512693 (UMLS CUI)
Schizophrenia | Schizoaffective Disorder | Schizophreniform Disorders
Item
1. diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform.
boolean
C0036341 (UMLS CUI [1])
C0036337 (UMLS CUI [2])
C0036358 (UMLS CUI [3])
Gender
Item
2. females who participate in this study:
boolean
C0079399 (UMLS CUI [1])
Infertility
Item
are unable to have children-or-
boolean
C0021359 (UMLS CUI [1])
Sexual Abstinence Willing
Item
are willing to remain abstinent from day -5 until 90 days after discharge;
boolean
C0036899 (UMLS CUI [1,1])
C0600109 (UMLS CUI [1,2])
Gender Sexual Abstinence Willing | Gender Contraceptive methods | Condoms, Male
Item
3. males must be willing to remain sexually abstinent or use an effective method of birth control (e.g. condom) from day -5 until 90 days after discharge.
boolean
C0079399 (UMLS CUI [1,1])
C0036899 (UMLS CUI [1,2])
C0600109 (UMLS CUI [1,3])
C0079399 (UMLS CUI [2,1])
C0700589 (UMLS CUI [2,2])
C0009653 (UMLS CUI [3])
Antipsychotic Agents Absent
Item
4. able and agree to remain off of prior antipsychotic medication for the duration of the study.
boolean
C0040615 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Medical condition Interferes with Absorption Lurasidone Oral Product | Medical condition Interferes with Metabolism Lurasidone Oral Product | Medical condition Interferes with Excretion Lurasidone Oral Product | Gastrointestinal Diseases | Operative Surgical Procedure Interferes with Absorption Lurasidone Oral Product | Operative Surgical Procedure Interferes with Metabolism Lurasidone Oral Product | Operative Surgical Procedure Interferes with Excretion Lurasidone Oral Product
Item
1. presence or history (within the last year) of a medical or surgical condition (e.g. gastrointestinal disease) that might interfere with the absorption, metabolism, or excretion of orally administered lurasidone.
boolean
C3843040 (UMLS CUI [1,1])
C0521102 (UMLS CUI [1,2])
C0237442 (UMLS CUI [1,3])
C3218141 (UMLS CUI [1,4])
C3843040 (UMLS CUI [2,1])
C0521102 (UMLS CUI [2,2])
C0025519 (UMLS CUI [2,3])
C3218141 (UMLS CUI [2,4])
C3843040 (UMLS CUI [3,1])
C0521102 (UMLS CUI [3,2])
C0221102 (UMLS CUI [3,3])
C3218141 (UMLS CUI [3,4])
C0017178 (UMLS CUI [4])
C0543467 (UMLS CUI [5,1])
C0521102 (UMLS CUI [5,2])
C0237442 (UMLS CUI [5,3])
C3218141 (UMLS CUI [5,4])
C0543467 (UMLS CUI [6,1])
C0521102 (UMLS CUI [6,2])
C0025519 (UMLS CUI [6,3])
C3218141 (UMLS CUI [6,4])
C0543467 (UMLS CUI [7,1])
C0521102 (UMLS CUI [7,2])
C0221102 (UMLS CUI [7,3])
C3218141 (UMLS CUI [7,4])
Positive Laboratory Test Result
Item
2. positive test results within 30 days prior to the start of the study for:
boolean
C1335447 (UMLS CUI [1])
Study Subject Participation Status | Investigational New Drugs
Item
3. participated in another clinical trial or receiving an investigational product within 30 days prior to drug administration.
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
Pharmaceutical Preparations Causing Prolonged QT interval | Pharmaceutical Preparations Causing Prolonged QTc interval
Item
4. use of concomitant medications that prolong the qt/qtc interval within 14 days prior to day - 5 to follow-up
boolean
C0013227 (UMLS CUI [1,1])
C0678227 (UMLS CUI [1,2])
C0151878 (UMLS CUI [1,3])
C0013227 (UMLS CUI [2,1])
C0678227 (UMLS CUI [2,2])
C1560305 (UMLS CUI [2,3])
Monoamine Oxidase Inhibitors
Item
5. use of a monoamine oxidase inhibitor within 21 days prior to day 1 to restabilization.
boolean
C0026457 (UMLS CUI [1])
Injection of depot antipsychotic agent
Item
6. received depot neuroleptics unless the last injection was at least 1 treatment cycle before day -5.
boolean
C2585377 (UMLS CUI [1])
Voltar ao início da página 

Contacto

Use este formulário para feedback, perguntas e sugestões de aperfeiçoamento.

Campos marcados com * são obrigatórios.

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial